TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ASKA Pharmaceutical Holdings Co., Ltd. ( (JP:4886) ) has issued an update.
ASKA Pharmaceutical Holdings Co., Ltd. has received a statement of intent from Dalton Investments, Nippon Active Value Fund PLC, and NAVF Select LLC regarding a large-scale purchase of the company’s share certificates. In response, ASKA has delivered an information list to these entities, requesting necessary information for shareholders and the board of directors to evaluate the purchase. This move is part of ASKA’s response policy to ensure transparency and informed decision-making in light of potential acquisition implications.
The most recent analyst rating on (JP:4886) stock is a Buy with a Yen2849.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.
More about ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co., Ltd. operates in the pharmaceutical industry, focusing on the development and distribution of pharmaceutical products. The company is based in Minato-ku, Tokyo, and is led by President and Representative Director Sohta Yamaguchi.
Average Trading Volume: 44,933
Technical Sentiment Signal: Buy
Current Market Cap: Yen67.6B
For an in-depth examination of 4886 stock, go to TipRanks’ Overview page.